 |
PDBsum entry 1af9
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Clostridial neurotoxin
|
PDB id
|
|
|
|
1af9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.24.68
- tentoxilysin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of 76-Gln-|-Phe-77 bond in synaptobrevin 2.
|
 |
 |
 |
 |
 |
Cofactor:
|
 |
Zn(2+)
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
Nat Struct Biol
4:788-792
(1997)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of the receptor binding fragment HC of tetanus neurotoxin.
|
|
T.C.Umland,
L.M.Wingert,
S.Swaminathan,
W.F.Furey,
J.J.Schmidt,
M.Sax.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The 2.7 A structure of the tetanus neurotoxin receptor binding fragment Hc
reveals a jelly-roll domain and a beta-trefoil domain. Hc retains the unique
transport properties of the holotoxin and is capable of eliciting a protective
immunological response against the full length holotoxin.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.F.Bongat,
R.Saksena,
R.Adamo,
Y.Fujimoto,
Z.Shiokawa,
D.C.Peterson,
K.Fukase,
W.F.Vann,
and
P.Kovác
(2010).
Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant.
|
| |
Glycoconj J,
27,
69-77.
|
 |
|
|
|
|
 |
P.Stenmark,
M.Dong,
J.Dupuy,
E.R.Chapman,
and
R.C.Stevens
(2010).
Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding.
|
| |
J Mol Biol,
397,
1287-1297.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.R.Popoff,
and
P.Bouvet
(2009).
Clostridial toxins.
|
| |
Future Microbiol,
4,
1021-1064.
|
 |
|
|
|
|
 |
Z.Fu,
C.Chen,
J.T.Barbieri,
J.J.Kim,
and
M.R.Baldwin
(2009).
Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F.
|
| |
Biochemistry,
48,
5631-5641.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Rummel,
T.Eichner,
T.Weil,
T.Karnath,
A.Gutcaits,
S.Mahrhold,
K.Sandhoff,
R.L.Proia,
K.R.Acharya,
H.Bigalke,
and
T.Binz
(2007).
Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept.
|
| |
Proc Natl Acad Sci U S A,
104,
359-364.
|
 |
|
|
|
|
 |
P.Chiarella,
E.Massi,
M.De Robertis,
E.Signori,
and
V.M.Fazio
(2007).
Adjuvants in vaccines and for immunisation: current trends.
|
| |
Expert Opin Biol Ther,
7,
1551-1562.
|
 |
|
|
|
|
 |
T.Suzuki,
H.Kouguchi,
T.Watanabe,
K.Hasegawa,
T.Yoneyama,
K.Niwa,
A.Nishikawa,
J.C.Lee,
K.Oguma,
and
T.Ohyama
(2007).
Effect of nicking the C-terminal region of the Clostridium botulinum serotype D neurotoxin heavy chain on its toxicity and molecular properties.
|
| |
Protein J,
26,
173-181.
|
 |
|
|
|
|
 |
O.Qazi,
D.Sesardic,
R.Tierney,
Z.Söderbäck,
D.Crane,
B.Bolgiano,
and
N.Fairweather
(2006).
Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.
|
| |
Infect Immun,
74,
4884-4891.
|
 |
|
|
|
|
 |
C.X.Moss,
S.P.Matthews,
D.J.Lamont,
and
C.Watts
(2005).
Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules.
|
| |
J Biol Chem,
280,
18498-18503.
|
 |
|
|
|
|
 |
S.Jayaraman,
S.Eswaramoorthy,
D.Kumaran,
and
S.Swaminathan
(2005).
Common binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin.
|
| |
Proteins,
61,
288-295.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Rummel,
S.Mahrhold,
H.Bigalke,
and
T.Binz
(2004).
The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction.
|
| |
Mol Microbiol,
51,
631-643.
|
 |
|
|
|
|
 |
C.Montecucco,
O.Rossetto,
and
G.Schiavo
(2004).
Presynaptic receptor arrays for clostridial neurotoxins.
|
| |
Trends Microbiol,
12,
442-446.
|
 |
|
|
|
|
 |
F.K.Stevenson,
C.H.Ottensmeier,
P.Johnson,
D.Zhu,
S.L.Buchan,
K.J.McCann,
J.S.Roddick,
A.T.King,
F.McNicholl,
N.Savelyeva,
and
J.Rice
(2004).
DNA vaccines to attack cancer.
|
| |
Proc Natl Acad Sci U S A,
101,
14646-14652.
|
 |
|
|
|
|
 |
F.K.Stevenson,
J.Rice,
C.H.Ottensmeier,
S.M.Thirdborough,
and
D.Zhu
(2004).
DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
|
| |
Immunol Rev,
199,
156-180.
|
 |
|
|
|
|
 |
K.A.Foster
(2004).
The analgesic potential of clostridial neurotoxin derivatives.
|
| |
Expert Opin Investig Drugs,
13,
1437-1443.
|
 |
|
|
|
|
 |
L.L.Simpson
(2004).
Identification of the major steps in botulinum toxin action.
|
| |
Annu Rev Pharmacol Toxicol,
44,
167-193.
|
 |
|
|
|
|
 |
G.Lalli,
S.Bohnert,
K.Deinhardt,
C.Verastegui,
and
G.Schiavo
(2003).
The journey of tetanus and botulinum neurotoxins in neurons.
|
| |
Trends Microbiol,
11,
431-437.
|
 |
|
|
|
|
 |
M.T.Reding,
D.K.Okita,
B.M.Diethelm-Okita,
T.A.Anderson,
and
B.M.Conti-Fine
(2003).
Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII.
|
| |
J Thromb Haemost,
1,
1777-1784.
|
 |
|
|
|
|
 |
K.Turton,
J.A.Chaddock,
and
K.R.Acharya
(2002).
Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.
|
| |
Trends Biochem Sci,
27,
552-558.
|
 |
|
|
|
|
 |
D.D.Pless,
E.R.Torres,
E.K.Reinke,
and
S.Bavari
(2001).
High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.
|
| |
Infect Immun,
69,
570-574.
|
 |
|
|
|
|
 |
V.I.Rotari,
P.M.Dando,
and
A.J.Barrett
(2001).
Legumain forms from plants and animals differ in their specificity.
|
| |
Biol Chem,
382,
953-959.
|
 |
|
|
|
|
 |
A.N.Antoniou,
S.L.Blackwood,
D.Mazzeo,
and
C.Watts
(2000).
Control of antigen presentation by a single protease cleavage site.
|
| |
Immunity,
12,
391-398.
|
 |
|
|
|
|
 |
J.J.Farrar,
L.M.Yen,
T.Cook,
N.Fairweather,
N.Binh,
J.Parry,
and
C.M.Parry
(2000).
Tetanus.
|
| |
J Neurol Neurosurg Psychiatry,
69,
292-301.
|
 |
|
|
|
|
 |
K.Sinha,
M.Box,
G.Lalli,
G.Schiavo,
H.Schneider,
M.Groves,
G.Siligardi,
and
N.Fairweather
(2000).
Analysis of mutants of tetanus toxin Hc fragment: ganglioside binding, cell binding and retrograde axonal transport properties.
|
| |
Mol Microbiol,
37,
1041-1051.
|
 |
|
|
|
|
 |
M.P.Byrne,
and
L.A.Smith
(2000).
Development of vaccines for prevention of botulism.
|
| |
Biochimie,
82,
955-966.
|
 |
|
|
|
|
 |
P.Emsley,
C.Fotinou,
I.Black,
N.F.Fairweather,
I.G.Charles,
C.Watts,
E.Hewitt,
and
N.W.Isaacs
(2000).
The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding.
|
| |
J Biol Chem,
275,
8889-8894.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.A.Johnson
(1999).
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
|
| |
Annu Rev Microbiol,
53,
551-575.
|
 |
|
|
|
|
 |
G.Rudenko,
T.Nguyen,
Y.Chelliah,
T.C.Südhof,
and
J.Deisenhofer
(1999).
The structure of the ligand-binding domain of neurexin Ibeta: regulation of LNS domain function by alternative splicing.
|
| |
Cell,
99,
93.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.C.Williamson,
K.E.Bateman,
J.C.Clifford,
and
E.A.Neale
(1999).
Neuronal sensitivity to tetanus toxin requires gangliosides.
|
| |
J Biol Chem,
274,
25173-25180.
|
 |
|
|
|
|
 |
R.Pellizzari,
O.Rossetto,
G.Schiavo,
and
C.Montecucco
(1999).
Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses.
|
| |
Philos Trans R Soc Lond B Biol Sci,
354,
259-268.
|
 |
|
|
|
|
 |
C.Watts,
A.Antoniou,
B.Manoury,
E.W.Hewitt,
L.M.Mckay,
L.Grayson,
N.F.Fairweather,
P.Emsley,
N.Isaacs,
and
P.D.Simitsek
(1998).
Modulation by epitope-specific antibodies of class II MHC-restricted presentation of the tetanus toxin antigen.
|
| |
Immunol Rev,
164,
11-16.
|
 |
|
|
|
|
 |
D.B.Lacy,
and
R.C.Stevens
(1998).
Unraveling the structures and modes of action of bacterial toxins.
|
| |
Curr Opin Struct Biol,
8,
778-784.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |